Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 822 participants.
Also called NCT02863328
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 822 participants
- Sponsor
- Registry
-
NCT02863328 -
2015-005209-36
-
- Main results
- Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Croatia, Greece, Hungary, Italy, Poland, Russia, Serbia, Spain, Thailand
- Registry status
- Completed
Technical summary
Registry record NCT02863328. Randomized; no masking; primary purpose treatment. Start 2016-08-10 (actual); primary completion 2017-08-01 (actual). Results posted on 2019-12-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
- Acronym
- PIONEER 2
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- empagliflozin
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02863328- Content hash
c198b12d492056bea4620c382c66489e6406ff4739263daecd7f29dfca086b5b